Sign in
Taking people in United StatesPhase 2/3

Tests timed blood pressure medicines in adults with obesity and high blood pressure

Tests sacubitril-valsartan and valsartan, timed to the day-night cycle, in adults with obesity.

Key facts

Who runs it
University of Alabama at Birmingham
Where
Birmingham, United StatesSee the site
Trial code
Registry title
PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis
Status
Recruiting
Phase
Phase 2/3
People taking part
160 people, planned
Started
18 Feb 2022
Expected to end
1 Jan 2027
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Sacubitril-Valsartan 49 Mg-51 Mg Oral Tablet
  • Valsartan 80 mg Oral Tablet
Record updated
9 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with obesity and mildly to moderately raised blood pressure. It studies the timing of blood pressure treatment over the day and night.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Body Mass Index (BMI) between 30 and 45 kg/m². Systolic blood pressure from 130 to 160 mmHg and diastolic from 80 to 100 mmHg. People with hypertension by the 2017 ACC/AHA Guidelines can join.
Earlier treatment
People taking 3 or more classes of blood pressure medicines at the maximum dose, or with resistant hypertension, cannot join.
Biomarker or test result
Kidney function (eGFR) must not be below 60 ml/min/1.73 m². Urine albumin creatinine ratio must be below 30 mg/g. Liver enzymes (AST and ALT) must not be above 3 times the upper limit of normal.

Main reasons for not taking part

  • Past or present heart or blood vessel disease, diabetes, stroke, TIA or seizure
  • History of pulmonary hypertension or angioedema
  • Anemia or significant psychiatric illness
  • Working night shifts or swing shifts
  • Pregnant or breastfeeding women, or women who can become pregnant without birth control

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Age more than or equal to 18 years of age
  • Body Mass Index between 30 to 45 kg/m\^2
  • Blood pressure: Systolic BP more than or equal to 130mmHg and less than or equal to 160mmHg and diastolic blood pressure more than or equal to 80mmHg and less than or equal to 100mmHg. Individuals with hypertension as per the 2017 ACC/AHA Guidelines will be eligible for enrollment

Who cannot take part

  • History of pulmonary hypertension
  • Have any past or present illness of cardiovascular disease including myocardial infarction, angina, cardiac arrhythmia, diabetes, stroke, TIA, or seizure
  • Participants who are taking 3 or more classes of hypertension medications on the maximum dose or with resistant hypertension
  • History of angioedema
  • Significant psychiatric illness
  • Estimated glomerular filtration rate (GFR) < 60 ml/min/1.73 m2 (CKD-EPI equation); urine albumin creatinine ratio ≥30 mg/g
  • Hepatic Transaminase (AST and ALT) levels >3x the upper limit of normal
  • Age less than 18, at screening
  • Systolic BP <130 or >160mmHg at baseline, or diastolic BP <80 or >100 mmHg at baseline
  • BMI <30 kg/m\^2 or >45 kg/m\^2
  • Anemia (men, Hct < 38%; women, Hct <36%)
  • Participants working night shifts or swing shifts
  • Women who are pregnant or breastfeeding or who can become pregnant and not practicing an acceptable method of birth control during the study (including abstinence)

Where in United States

  • University of Alabama at BirminghamBirmingham, United StatesContact: Nehal Vekariya, MSTaking people

About the trial

What the trial wants to find out

Obese individuals have a higher prevalence of nocturnal hypertension and non-dipping blood pressure (BP). These conditions are associated with an increased risk of cardiovascular (CV) events and death. Natriuretic Peptides (NPs) are hormones produced by the heart which directly regulate BP by causing dilation of blood vessels and by removing sodium and water from the body. NPs have a 24-hour day-night rhythm and this controls the day-night rhythm of BP as well. The NP-BP rhythm relationship is broken down in obese individuals. Obese individuals also have lower circulating NP levels. Lower circulating levels of NPs and elevated renin hormone (a part of the Renin-Angiotensin-Aldosterone System [RAAS]) at nighttime may contribute to the high nocturnal blood pressure in obese individuals which puts them at a higher risk of developing CV events. This current study seeks to determine the biological implications of chronopharmacology for synchronizing NP-RAAS-based blood pressure therapy with the physiological diurnal rhythms to restore the normal diurnal rhythm of blood pressure in obese individuals.

The 4 groups in the trial

  • Sacubitril/Valsartan Morning DoseTreatment being tested

    We will enroll 40 adult obese individuals. Each participant will take the assigned dose of medication once in the morning and a placebo pill in the evening for 28 days. We evaluate Natriuretic Peptide-Renin-Angiotensin-Aldosterone System Rhythm Axis and Nocturnal Blood Pressure at baseline and after 28 days of intervention.

    Treatment: Sacubitril-Valsartan 49 Mg-51 Mg Oral Tablet

  • Sacubitril/Valsartan Evening DoseTreatment being tested

    We will enroll 40 adult obese individuals. Each participant will take the assigned dose of medication once in the evening and a placebo pill in the morning for 28 days. We evaluate Natriuretic Peptide-Renin-Angiotensin-Aldosterone System Rhythm Axis and Nocturnal Blood Pressure at baseline and after 28 days of intervention.

    Treatment: Sacubitril-Valsartan 49 Mg-51 Mg Oral Tablet

  • Valsartan Morning DoseExisting treatment, for comparison

    We will enroll 40 adult obese individuals. Each participant will take the assigned dose of medication once in the morning and a placebo pill in the evening for 28 days. We evaluate Natriuretic Peptide-Renin-Angiotensin-Aldosterone System Rhythm Axis and Nocturnal Blood Pressure at baseline and after 28 days of intervention.

    Treatment: Valsartan 80 mg Oral Tablet

  • Valsartan Evening DoseExisting treatment, for comparison

    We will enroll 40 adult obese individuals. Each participant will take the assigned dose of medication once in the evening and a placebo pill in the morning for 28 days. We evaluate Natriuretic Peptide-Renin-Angiotensin-Aldosterone System Rhythm Axis and Nocturnal Blood Pressure at baseline and after 28 days of intervention.

    Treatment: Valsartan 80 mg Oral Tablet

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Natriuretic Peptide-Renin-Angiotensin-Aldosterone System Rhythm Axis and Nocturnal Blood Pressure
Plain-language title
Tests timed blood pressure medicines in adults with obesity and high blood pressureGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
9 April 2026